tirzepatide injection thurmont B6 Vial | Weight Loss Treatment Zepbound Tirzepatide Injection 15 mg/0.5

Because tirzepatide (brand name Mounjaro) was only approved by the FDA in mid-2022 for type 2 diabetes, the ability to rigorously analyze its use (on- and off-label) for a broad population of patients with overweight or obesity, not just a subset captured in insurance databases, has the power to greatly improve our understanding of how these agents are being used in every day practice and the effect that theyre having.

For individuals starting Tirzepatide, healthcare providers generally prescribe an initial dose of 2.5 mg , injected subcutaneously once a week

This data directly informs the storage guidelines printed on the label

This matters more after stopping tirzepatide because the medication improved glucose metabolism directly

As you begin treatment, you may experience mild side effects such as nausea, fatigue, or constipation, especially in the early weeks